The purpose of this study is:
1. To provide continued pelabresib treatment to patients who have previously received pelabresib in a parent study and continue collecting safety and efficacy information
2. To evaluate the overall survival and leukemia-free survival of patients who discontinued placebo or pelabresib treatment in pelabresib parent studies

Start Date13 Aug 2024

Sponsor / Collaborator

Constellation Pharmaceuticals, Inc.

NCT05391022 / CompletedPhase 1

A Phase 1, 2-Part Study to Evaluate the Effect of Food on Pharmacokinetics of Pelabresib (CPI-0610) and the Effect of Pelabresib on QTc in Patients With Advanced Malignancies

Phase 1 2-part study to evaluate the effect of food on pharmacokinetics of pelabresib (CPI-0610) and the effect of pelabresib on QTc in patients with advanced malignancies

Start Date20 Jul 2021

Sponsor / Collaborator

Constellation Pharmaceuticals, Inc.

NCT04603495 / Active, not recruitingPhase 3

A Phase 3, Randomized, Double-blind, Active-Control Study of Pelabresib (CPI-0610) and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients

A Phase 3, randomized, blinded study comparing pelabresib (CPI-0610) and ruxolitinib with placebo and ruxolitinib in myelofibrosis (MF) patients that have not been previously treated with Janus kinase inhibitors (JAKi). Pelabresib is a small molecule inhibitor of bromodomain and extra-terminal (BET) proteins.

Start Date09 Apr 2021

Sponsor / Collaborator

Constellation Pharmaceuticals, Inc.

100 Clinical Results associated with Pelabresib

100 Translational Medicine associated with Pelabresib

100 Patents (Medical) associated with Pelabresib

Literatures (Medical) associated with Pelabresib

01 May 2024·American journal of hematology

New drugs in myelofibrosis: Critical assessment of additional value to monotherapy with JAK inhibitors

Letter

Author: Tefferi, Ayalew ; Gangat, Naseema

Ruxolitinib in combination with navitoclax or pelabresib in myelofibrosis: activity in JAKi-naïve patients.

12 Apr 2024·EXPERT OPINION ON PHARMACOTHERAPY

Advances in pharmacotherapy for myelofibrosis: what is the current state of play?

Review

Author: Tiribelli, Mario ; Morelli, Gianluca ; Bonifacio, Massimiliano

INTRODUCTION:

The introduction of the first JAK inhibitor (JAKi) ruxolitinib 10 years ago represented a pivotal advancement in myelofibrosis (MF) treatment, mostly in terms of spleen and symptoms response. Nowadays three more JAKi, fedratinib, pacritinib, and momelotinib, are available for both ruxolitinib-resistant and naïve patients. Moreover, many drugs are currently being investigated, both alone and in combination with JAKi.

AREAS COVERED:

In this review we discuss the long-term data of ruxolitinib and more recent evidence coming from clinical trials of fedratinib, pacritinib, and momelotinib, used as first- or second-line MF therapy. More, focus is set on data from non-JAKi drugs, such as the quite extensively studied BET-inhibitors (pelabresib) and BCL-inhibitors (navitoclax), novel target therapies, and drugs aimed to improve anemia, still representing a major determinant of reduced survival in MF.

EXPERT OPINION:

It's now evident that JAKi monotherapy, though clinically effective, is rarely able to change MF natural history; novel drugs are promising but long-term data are inevitably lacking. We feel that soon MF treatment will require clinicians to select the most appropriate JAKi inhibitor, based on patient characteristics, associating either front-line or in case of early suboptimal response, non-JAKi drugs with the aim to pursue disease modification.

20 Mar 2024·Leukemia & lymphoma

Results from phase 1 of the MANIFEST clinical trial to evaluate the safety and tolerability of pelabresib in patients with myeloid malignancies

Article

Author: Fathi, Amir T. ; Colak, Gozde ; Fusco, Andrea ; Harb, Wael A. ; Stein, Eytan M. ; Mangan, James K.

Pelabresib (CPI-0610), a BET protein inhibitor, is in clinical development for hematologic malignancies, given its ability to target NF-κB gene expression. The MANIFEST phase 1 study assessed pelabresib in patients with acute leukemia, high-risk myelodysplastic (MDS) syndrome, or MDS/myeloproliferative neoplasms (MDS/MPNs) (NCT02158858). Forty-four patients received pelabresib orally once daily (QD) at various doses (24-400 mg capsule or 225-275 mg tablet) on cycles of 14 d on and 7 d off. The most frequent drug-related adverse events were nausea, decreased appetite, and fatigue. The maximum tolerated dose (MTD) was 225 mg tablet QD. One patient with chronic myelomonocytic leukemia (CMML) showed partial remission. In total, 25.8% of acute myeloid leukemia (AML) patients and 38.5% of high-risk MDS patients had stable disease. One AML patient and one CMML patient showed peripheral hematologic response. The favorable safety profile supports the ongoing pivotal study of pelabresib in patients with myelofibrosis using the recommended phase 2 dose of 125 mg tablet QD.CLINICAL TRIAL REGISTRATION: NCT02158858.

News (Medical) associated with Pelabresib

25 Nov 2024

·www.globenewswire.com

Novartis highlights new 96-week results from Phase III Scemblix® ASC4FIRST trial at ASH and late-breaking analysis from Phase III Kisqali® NATALEE trial at SABCS

Longer-term 96-week results from Scemblix® ASC4FIRST Phase III study in first-line Ph+ CML-CP to be presented following recent FDA approval based on 48-week data Late-breaking Kisqali®* 4-year analysis on distant disease-free survival in key subgroups with HR+/HER2- early breast cancer from Phase III NATALEE trial also to be presentedPipeline updates demonstrate advancement in research and development programs in hematologic diseases and cancers Basel, November 25, 2024 – Novartis will present data from more than 65 abstracts, including investigator-initiated trials at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition and the 2024 San Antonio Breast Cancer Symposium® (SABCS). “By prioritizing research in areas of greatest medical need and focusing on earlier stages of disease, we aim to change the treatment paradigm for people who require additional treatment options,” said Jeff Legos, Executive Vice President, Global Head of Oncology Development, Novartis. “The new data being presented at ASH and SABCS underscore our commitment to patients with cancer or blood disorders and follow new, expanded indications for Scemblix and Kisqali along with recent updates in national treatment guidelines." In addition to late-breaking data, Novartis will host an art gallery-style exhibit at SABCS featuring personal letters and stories written by people impacted by breast cancer, sharing their raw, authentic perspectives on aspects of the breast cancer journey. These letters and stories aim to uplift patients, encourage reflection, and demonstrate strength and unity among the breast cancer community. Key abstracts accepted by ASH include: Medicine or Disease State      Abstract Title      Abstract Number/ Presentation Details       Scemblix®Asciminib (ASC) Demonstrates Favorable Safety and Tolerability Compared with Each Investigator-Selected Tyrosine Kinase Inhibitor (IS TKI) in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) in the Pivotal Phase 3 ASC4FIRST Study Abstract #475Oral PresentationSunday, December 89:30 – 11:00 AM PTScemblix   Efficacy and Safety of Asciminib in Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Interim Results from the Phase 2 ASC2ESCALATE Trial in the Cohort of Patients (Pts) after 1 Prior Tyrosine Kinase Inhibitor (TKI) Abstract #479Oral PresentationSunday, December 89:30 – 11:00 AM PTScemblix Asciminib Shows High Efficacy and Favorable Tolerability at 80 Mg Once Daily and 40 Mg Twice Daily in Patients with Chronic Phase Chronic Myelogenous Leukemia Previously Treated with 2 or More Tyrosine Kinase Inhibitors: Primary Analysis from the ASC4OPT Study Abstract #4526Poster PresentationMonday, December 96:00 – 8:00 PM PTScemblix Treatment with Asciminib as a Second Line after One Prior Tyrosine Kinase Inhibitor (TKI) in Patients with Chronic-Phase Chronic Myeloid Leukemia (CML-CP)– a Chart Review Study in the United States Abstract #3812Poster PresentationSunday, December 86:00 – 8:00 PM PTIanalumab (VAY736)A Phase 2 Study of Ianalumab in Patients with Primary Immune Thrombocytopenia Previously Treated with at Least Two Lines of Therapy: Interim Results from VAYHIT3 Abstract #710Oral PresentationMonday, December 910:30 AM – 12:00 PM PTRapcabtagene autoleucel (YTB323)Rapcabtagene Autoleucel (YTB323) in Patients (Pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Phase II Trial Clinical Update Abstract #67Oral PresentationSaturday, December 79:30 – 11:00 AM PTFabhalta®Oral Iptacopan Monotherapy Leads to Long-Term Improvements in Patient (Pt)-Reported Health-Related Quality of Life (HRQoL) and Investigator-Assessed Signs and Symptoms of Paroxysmal Nocturnal Hemoglobinuria (PNH): 48-Week (Wk) Results from the Phase III APPLY-PNH and APPOINT-PNH Trials Abstract #4079Poster PresentationMonday, December 96:00 – 8:00 PM PTFabhalta The Effect of Oral Iptacopan Monotherapy on Hematological Parameters in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Is Consistent Regardless of the Type of Prior Anti-C5 Treatment Received: A Post Hoc Analysis of 24-Week Data from the Randomized Phase III APPLY-PNH Trial Abstract #4087Poster PresentationMonday, December 96:00 – 8:00 PM PTFabhalta Baseline Characteristics of Individuals with Paroxysmal Nocturnal Hemoglobinuria in an App-Based Home-Reported Outcomes Study to Evaluate Disease Burden Abstract #2327Poster PresentationSaturday, December 75:30 – 7:30 PM PTPelabresib (CPI-0610)Updated Results from the Phase 3 Manifest-2 Study of Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor–Naïve Patients with MyelofibrosisAbstract #3178Poster PresentationSunday, December 86:00 PM - 8:00 PM PT Key abstracts accepted by SABCS include: Medicine or Disease State      Abstract Title      Abstract Number/ Presentation Details       Kisqali® (ribociclib)* Distant disease-free survival (DDFS) across key subgroups from the phase 3 NATALEE trial of ribociclib (RIB) plus a nonsteroidal aromatase inhibitor (NSAI) in patients with HR+/HER2- early breast cancer (EBC) Abstract #P4-09-22Poster SessionThursday, December 125:30 – 7:30 PM CST Kisqali     Impact of ribociclib dose reduction on efficacy in patients with hormone receptor– positive/human epidermal growth factor receptor 2–negative (HR+/HER2-) early breast cancer (EBC) in NATALEE Abstract #P1-11-16Poster Session Wednesday, December 1112:30 – 2:00 PM CSTKisqali Risk of recurrence in real-world (RW) NATALEE- and monarchE-eligible populations of patients with HR+/HER2- early breast cancer (EBC) in an electronic health record (EHR)-derived database Abstract #P2-12-02Poster SessionWednesday, December 115:30 – 7:00 PM CST Kisqali Tolerability of First-Line (1L) Treatment (tx) With Ribociclib (RIB) for Metastatic Breast Cancer (MBC) Using 2 Large US Data Sources Abstract #P3-10-14Poster SessionThursday, December 1212:30 – 2:00 PM CST Kisqali Impact of body mass index (BMI) on the safety and efficacy of ribociclib (RIB) in patients (pts) with HR+/HER2- advanced breast cancer (ABC): pooled analysis of the MONALEESA (ML)-2, -3, and -7 trials Abstract #P2-09-20Poster SessionWednesday, December 115:30 – 7:00 PM CST Kisqali First-line (1L) ribociclib (RIB) + endocrine therapy (ET) vs combination chemotherapy (combo CT) in clinically aggressive HR+/HER2- advanced breast cancer (ABC): a subgroup analysis of RIGHT Choice by intrinsic subtype & gene & signature expression Abstract #PS2-06Poster PresentationThursday, December 127:00 – 8:30 AM CST Product Information     For full prescribing information, including approved indications and important safety information about marketed products, please visit https://www.novartis.com/about/products. DisclaimerThis press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise. About Novartis Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. Reimagine medicine with us: Visit us at https://www.novartis.com and connect with us on LinkedIn, Facebook, X/Twitter and Instagram. # # # * Kisqali was developed by Novartis under a research collaboration with Astex Pharmaceuticals. Novartis Media RelationsE-mail: media.relations@novartis.com Central North America Anja von Treskow+41 79 392 9697Michael Meo+1 862 274 5414Anna Schäfers+41 79 801 7267 SwitzerlandSatoshi Sugimoto +41 79 619 2035 Novartis Investor RelationsCentral investor relations line: +41 61 324 7944E-mail: investor.relations@novartis.com Central North America Isabella Zinck+41 61 324 7188Sloan Simpson+1 862 345 4440Nicole Zinsli-Somm+41 61 324 3809Jonathan Graham+1 201 602 9921Imke Kappes+41 61 324 8269Parag Mahanti+1 973 876 4912

Phase 3Clinical ResultPhase 2ASH

21 Nov 2024

·endpts.com

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

Novartis is buying gene therapy and neuroscience biotech Kate Therapeutics in a deal worth $1.1 billion in upfront and milestone payments, the Swiss pharma confirmed to Endpoints News on Thursday. And Novartis is not done yet. It is still on the lookout for bolt-on M&A opportunities — but don’t expect them to go higher than $3 billion. “That’s not that we couldn’t do a little bit bigger, but that’s the majority of the available target companies, if you will,” Novartis CFO Harry Kirsch told the media ahead of its investor event in London on Thursday. CEO Vas Narasimhan added that a lot of M&A from the recent past has been in the $1 billion to $2 billion range, pointing to its acquisitions of Mariana Oncology and KateTx. Over the past eight years, it made $5 billion to $10 billion deals only “occasionally” because of valuation considerations and “financial discipline,” he added. Novartis will take on KateTx’s pipeline of preclinical candidates in Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy and myotonic dystrophy type 1. The San Diego biotech’s gene therapy tech features adeno-associated virus capsids that deliver their payloads into specific tissues to avoid off-target issues such as hepatic side effects. In June 2023, it said that it was partnering with Astellas on a neuromuscular disease called X-linked myotubular myopathy. Novartis revealed its purchase of KateTx ahead of its Meet Novartis Management event in London that was intended to reassure investors its pure-play strategy is bearing fruit now and in the next several years. A key part of its growth strategy is more M&A as “replacement power,” with the company facing the loss of exclusivity for key drugs such as Entresto , Kirsch said. When asked if changes to the Federal Trade Commission could lead to Novartis raising its M&A budget, Narasimhan said the FTC is not a major driver of its decisions. As a part of its reorg, the company zeroed in on four therapeutic spaces: cardiovascular-renal-metabolic, immunology, neuroscience and oncology. “Preclinical, Phase 1, Phase 2 area — that’s the opportunity where we can step in” and Novartis can add value to the acquired company, Narasimhan said, adding that it’s challenging to “find synergies, harder to justify” with later-stage candidates. Narasimhan said that when it bought MorphoSys for $2.9 billion, its lead oncology candidate , pelabresib, was in an ongoing Phase 3 trial. “We saw the opportunity in an area of myelofibrosis that we’ve been in for a long period of time, and we took a bet on an ongoing clinical trial,” he said, adding that if it had waited for the late-stage readout, the purchase price would have been “double at least.” But that bet on MorphoSys led to the company taking an $800 million impairment hit just months after the deal closed due to emergent malignancies. “In this case, it didn’t go our way,” he said, nonetheless noting the company’s overall M&A track record . As for pelabresib, the company’s next update should come in the second half of next year. Narasimhan said it is monitoring patients until the middle of next year. “We are also planning to conduct additional studies to look at certain subpopulations of myelofibrosis patients where pelabresib could have a better benefit-risk profile. So I think all of that will take us at least until 2027 — it might take longer, depending on the safety topic,“ he added.

AcquisitionPhase 3Phase 2Gene TherapyPhase 1

29 Oct 2024

·endpts.com

Novartis highlights overall M&A track record following MorphoSys impairment

Novartis CEO Vas Narasimhan assured investors on Tuesday that it takes a careful, systematic approach to M&A after recording an $800 million impairment to its recent MorphoSys acquisition. During the company’s third-quarter earnings call, Narasimhan said that he sees its overall M&A success rate as “in line with the overall sector.” The MorphoSys impairment , recorded just five months after Novartis closed the deal, was related to clinical data for the company’s myelofibrosis candidate pelabresib. “Whenever you do clinical-stage deals like we did with pelabresib, you will have updated clinical data,” he said in response to an analyst question about investor confidence. “I would expect sophisticated investors not to read too much into one-offs, but rather look at the overall portfolio of how a company does [and] executes M&A.” Novartis is delaying its regulatory submission for the candidate, as it needs more time to follow patients and assess concerns about emergent malignancies. The company’s stock $NVS was down roughly 3% on Tuesday afternoon. Narasimhan said Novartis has “adequate firepower” for dealmaking, share buybacks and other investments. He cited the company’s recent $1 billion deal to acquire radiopharmaceutical startup Mariana Oncology and another deal struck earlier this week for Monte Rosa Therapeutics’ molecular glue candidate. “We can do all M&A bolt-on deals that we come up with,” CFO Harry Kirsch said, adding that “it’s not so easy to come up with good ones given the premiums one has to pay and the high conviction we have to have.” As for Novartis’ appetite for M&A in immunology, Narasimhan said the focus is broadly around reinforcing the company’s efforts in bispecifics or cell therapy, “or to look at novel targets like Monte Rosa that we recently have done.”

AcquisitionCell Therapy

100 Deals associated with Pelabresib

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Advanced cancer	Phase 3	US	Constellation Pharmaceuticals, Inc.	13 Aug 2024
Advanced cancer	Phase 3	BE	Constellation Pharmaceuticals, Inc.	13 Aug 2024
Advanced cancer	Phase 3	IT	Constellation Pharmaceuticals, Inc.	13 Aug 2024
Advanced cancer	Phase 3	NL	Constellation Pharmaceuticals, Inc.	13 Aug 2024
Advanced cancer	Phase 3	GB	Constellation Pharmaceuticals, Inc.	13 Aug 2024
Leukemia	Phase 3	US	Constellation Pharmaceuticals, Inc.	13 Aug 2024
Leukemia	Phase 3	BE	Constellation Pharmaceuticals, Inc.	13 Aug 2024
Leukemia	Phase 3	IT	Constellation Pharmaceuticals, Inc.	13 Aug 2024
Leukemia	Phase 3	NL	Constellation Pharmaceuticals, Inc.	13 Aug 2024
Leukemia	Phase 3	GB	Constellation Pharmaceuticals, Inc.	13 Aug 2024

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04603495 (MANIFEST-2, CTgov)	Phase 3	Post-essential thrombocythemia myelofibrosis \| Post-polycythemia vera myelofibrosis \| Primary Myelofibrosis	430	Ruxolitinib+Pelabresib (Pelabresib + Ruxolitinib)	iwmbdjyfqm(rbxnphjzgg) = cnwnauujqm twoahwbdks (ntwlfjmoft, mdswcmrpel - wgkprcgsrd) View more	-	28 Oct 2024
				Placebo+Ruxolitinib (Placebo + Ruxolitinib)	iwmbdjyfqm(rbxnphjzgg) = limnlxlbew twoahwbdks (ntwlfjmoft, cwdnythcfz - aysyzpmlju) View more
SOHO2024	Not Applicable	Myelofibrosis	-	Pelabresib+ruxolitinib	sathanauyn(eyepemblsi) = 43.9% vs 54.7% dgnxfflaip (wxxwudffff ) View more	-	04 Sep 2024
				Placebo+ruxolitinib
NCT04603495 (MANIFEST-2, ASCO2024) Manual	Phase 3	Myelofibrosis	430	Pelabresib + Ruxolitinib	lxnzjzqsld(sybqscndxa) = fmuuqqslqa faoofqwqgq (pojzlrjebp ) View more	Positive	24 May 2024
				Placebo + Ruxolitinib	lxnzjzqsld(sybqscndxa) = kvhdgoubxq faoofqwqgq (pojzlrjebp ) View more
NCT02158858 (MANIFEST, Pubmed) Manual	Phase 1	Myeloid Tumor Protein Expression Markers	44	Pelabresib	nasgpwoduj(jixxvodtyq) = nausea, decreased appetite, and fatigue kfedplawbj (njjwlftttm ) View more	Positive	23 Jan 2024
				Pelabresib (acute leukemia)
NCT04603495 (MANIFEST-2, Corporate Publications) Manual	Phase 3	Primary Myelofibrosis	430	Pelabresib + Ruxolitinib	xibzczmvtj(ykgeyaoxux) = qovswfated ezdefdjuft (ewgjknfnmi ) Met View more	Positive	20 Nov 2023
				Placebo + Ruxolitinib	xibzczmvtj(ykgeyaoxux) = xppnifmnpd ezdefdjuft (ewgjknfnmi ) Met View more
NCT02158858 (MANIFEST, EHA2023)	Phase 2	Acute Myeloid Leukemia \| Thrombocytopenia \| Hematologic Neoplasms ... View more	84	PELA + RUX	wwdxhcnncu(amusglzwxo) = gbigsrruee utpcldcdtw (llcewvaojw ) View more	-	08 Jun 2023
NCT02158858 (MANIFEST, EHA2023)	Phase 2	Primary Myelofibrosis Add-on	87	PELA + RUX	fnvsppujxr(hwqsnmzxuw) = xcfpklosha mmomiajoxk (fzxontohia ) View more	-	08 Jun 2023
NCT02158858 (ASCO2023) Manual	Phase 1/2	Thrombocythemia, Essential	20	Pelabresib 225mg	tzeyjyilet(odolnpdagk) = bfeivksusd offeeeytko (llrvfaqvjp ) View more	Positive	31 May 2023
NCT02158858 (MANIFEST, ASH2022) Manual	Phase 2	Primary Myelofibrosis	86	Ruxolitinib+Pelabresib	bequxvqqjt(dixzrabdzj) = sxwvgploxs jltcqwliwe (lnzpvyzqvg ) View more	Positive	15 Nov 2022
				Ruxolitinib+Pelabresib (transfusion dependen(Arm 2A))	bequxvqqjt(dixzrabdzj) = makextykfw jltcqwliwe (lnzpvyzqvg ) View more
SOHO2022	Not Applicable	Myelofibrosis	-	Pelabresib combined with Ruxolitinib	yiiplyyvqp(zlbuqkbxeq) = Low-grade gastrointestinal TEAEs and respiratory infections were observed but rarely resulted in discontinuation uvoirsljat (gebmabagqj )	-	01 Oct 2022
				Ruxolitinib

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis